Preparation and Evaluation of 131I-Quercetin As a Novel Radiotherapy Agent Against Dedifferentiated Thyroid Cancer

Qinghua Xie,Xia Li,Guanquan Wang,Xuan Hou,Yujun Wang,Hongbo Yu,Changfa Qu,Shunzhong Luo,Yali Cui,Chuanqin Xia,Ruibing Wang
DOI: https://doi.org/10.1007/s10967-016-5143-4
2016-01-01
Journal of Radioanalytical and Nuclear Chemistry
Abstract:Here we reported the radiolabeling and evaluation of a novel 131I-radiolabeled quercetin for the treatment of dedifferentiated thyroid cancers. The human thyroid cancer cell lines (FTC-133, TT and DRO) experienced much higher uptake of 131I-quercetin as compared to the free 131I. And the proliferation inhibition rate of 131I-quercetin on in vitro DRO cell line was 86.87 ± 7.15%. Biodistribution and SPECT analysis demonstrated that the injected radioactivity mainly accumulated in tumors. The tumor volume in the treatment group was dramatically inhibited in comparison with the control group.
What problem does this paper attempt to address?